DVDeepak Vashisht

Deepak Vashisht

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Deepak Vashisht has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An Enigmatic Case of Focal Sweating: Naevus Sudoriferous

    by Deepak Vashisht, Preema Sinha, Parul Kamboj, Manoj G. Madakshira, Kumar Alok, Juhi Sharma

    Citation: Vashisht D, Sinha P, Kamboj P, Madakshira MG, Alok K, Sharma J. An Enigmatic Case of Focal Sweating: Naevus Sudoriferous. Dermatol Pract Concept. 2023;13(2):e2023070. DOI: https://doi.org/10.5826/dpc.1302a70 Accepted: June 20, 2022; Published: April 2023 Copyright: ©2023 Vashisht et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Juhi Sharma, Department of Dermatology, Command Hospital, Lucknow, India 226002, Email: drjuhisharma.sharma17@gmail.com Keywords : eccrine, sudoriferous, dermoscopy, vaporimeter, histopathology This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

  • Descriptive study of sweat dermatitis: A rare dermatoses not so rare in tropics

    by Deepak Vashisht, Parul Kamboj, Chaudhary Sampoorna Raj, Manoj Gm, Preema Sinha, Sukriti Baveja, Aradhana Sood, Rajneesh Joshi

  • Open Access

    Falkner’s needling technique for the treatment of warts: Minimum investment, maximum benefit

    by Sukriti Baveja, Siddharth Bhatt, Surbhi Vashisht, Deepak Vashisht, Rajneesh Joshi, Vikas Pathania, Ruby Venugopal


  • Open Access

    Dermoscopy of Dermatomyositis in Dark Skin

    by Shekhar Neema, Rohit Kothari, Ahmed Waheed Kashif, Deepak Vashisht, Biju Vasudevan

    Citation:  Neema S, Kothari R, Kashif AW, Vashisht D, Vasudevan B. Dermoscopy of dermatomyositis in dark skin. Dermatol Pract Concept. 2022;12(1):e2022013. DOI: https://doi.org/10.5826/dpc.1201a13 Accepted: May 8, 2021; Published: January 2022 Copyright: ©2022 Neema et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Shekhar Neema MD, FEBDV, Associate Professor, Armed Forces Medical College, Pune, India. Email. shekharadvait@gmail.com Keywords : dermatomyositis, dark skin, hyperpigmentation This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


  • Open Access

    Trichoscopy of Pressure-Induced Alopecia and Alopecia Areata

    by Shekhar Neema, Deepak Vashisht, Arun K. Yadav, Anwita Sinha, S. Radhakrishnan

    Background: Pressure-induced alopecia is an uncommon type of alopecia. It can occur in both scarring as well as non-scarring form and occurs due to ischemia resulting from prolonged head immobilisation during surgery or hospitalisation. The patchy hair loss generally involves convexities of scalp specially vertex and occiput. The hair loss is usually noticed 3 -28 days after the inciting event and regrowth of hair occurs between 1 – 4 months. Objective: To describe trichoscopic features of pressure alopecia and compare it with the closest differential, alopecia areata. Methodology: It is a retrospective observational study. Trichoscopic features of six cases of pressure alopecia seen during the study period were compared with alopecia areata and analyzed using appropriate statistical methods. Results: The study had 30 cases, six cases of pressure alopecia and 24 cases of alopecia areata. The mean age of patients with pressure alopecia and alopecia areata was 45.16 and 29.08 years respectively. Comedone- like black dots, black dots and area of scarring were statistically significant for pressure alopecia while exclamation mark hairs were significant for alopecia areata. Conclusion: Trichoscopy is a non-invasive test for diagnosis of alopecia and “Comedone-like black dots” are unique trichoscopic feature of pressure alopecia.


  • Open Access

    An uncommon phenomenon with common medications in a case of bi‐segmental vitiligo

    by Rohit Kothari, Durga Madhab Tripathy, Sunmeet Sandhu, Deepak Vashisht, Siddharth Bhatt, Amol Gopal Rathod


  • Copper-impregnated socks: A novel therapeutic option for combating occupational dermatophytosis

    by Sukriti Baveja, Chetan C. Patil, Surbhi Vashisht, Deepak Vashisht, Vikas Pathania, Durga Tripathy, Bhavni Oberoi

  • Recurrent erythema nodosum leprosum associated with Mycobacterium indicus pranii vaccine in a case of leprosy: a rare paradox

    by R. Kothari, D. Vashisht, N. Pudasaini, R. Venugopal, G. Paliwal

    Erythema nodosum leprosum (ENL) is the commonest manifestation of type 2 lepra reaction (T2LR) due to immune complex mediated inflammation in patients of lepromatous (LL) and borderline lepromatous (BL) leprosy. Vaccines given as immunotherapy in leprosy may expedite early smear negativity and may hasten complete recovery. However, vaccination can also be associated with reactions. Majority of vaccine induced lepra reactions were reported about five decades back in the era of smallpox vaccination.


  • Drug reaction with eosinophilia and systemic symptoms: A single center descriptive observational study

    by Sunmeet Sandhu, Shekhar Neema, Deepak Vashisht, Ruby Venugopal, Prashant Sengupta, Subramaniyan Radhakrishnan

    Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe adverse cutaneous drug reaction with mortality up to 10%. It is a rare condition with risk varying between 1 in 1000 and 1 in 10 000 drug exposures. The aim of the study was to describe clinical features, management and drugs responsible for causing DRESS. The study was retrospective, observational study. The data of patients admitted to hospital with diagnosis of DRESS during study period (March 2018 to February 2020), were retrieved and analyzed. The descriptive data of patients were summarized. The continuous variables were summarized as mean +/- SD and/or median, depending on the skewness of the data. The categorical variables were expressed as absolute numbers, frequency, and proportions (%). The data was tabulated and analyzed in Microsoft Excel 2019 version. A total of 20 patients who met inclusion criteria (probable or definite DRESS as per RegiSCAR criteria) were included in the study. The mean age of the patients was 41.2 +/- 15.7 years. The average latency period was 26.45 +/- 5.65 days (range: 7-60). The commonest culprit drugs were dapsone and phenytoin, each in five (25%) patients. Commonest morphology of rash was morbilliform in 13 (65%) patients. One patient with targetoid rash had multi-organ involvement. Facial edema, periorbital edema, and conjunctival injection were seen in 17 (85%), seven (35%), and six (30%) cases, respectively. Eosinophilia was present in 18 (90%) patients with mean (+/- SD) value of 1976 +/- 840 cells/mu l. Liver was the commonest internal organ involved in 14 (70%) patients and kidney in three (15%) patients. The initial dose of prednisolone for treatment varied from 0.75 to 2 mg/kg/day. The mean duration of steroid treatment was 64 +/- 21 days. Two patients were treated with intravenous methylprednisolone and one with intravenous immunoglobulin. Two patients (10%) had recurrence of adverse drug reaction >6 months after completion of initial treatment and two (10%) developed autoimmune thyroiditis during follow-up. Small sample size and retrospective nature of the study were main limitations. Selection bias is a possibility as study was carried out in tertiary care center. Tests for incriminating culprit drugs such as patch test, intradermal test, and lymphocyte transformation test were not performed. DRESS is a rare disease that can be diagnosed early with high index of suspicion and treated successfully with steroids. The internal organ involvement is common in DRESS and requires a thorough evaluation.